We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

186 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more call options, than puts

Call options by funds: $7.03M | Put options by funds: $2.73M

62% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 29

11% more funds holding

Funds holding: 168 → 186 (+18)

7% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 55

0.57% more ownership

Funds ownership: 108.71% → 109.28% (+0.57%)

5% less capital invested

Capital invested by funds: $1.24B → $1.18B (-$61.9M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
186
Holders Change
+18
Holders Change %
+10.71%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
47
Increased
59
Reduced
55
Closed
29
Calls
$7.03M
Puts
$2.73M
Net Calls
+$4.3M
Net Calls Change
+$8.98M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$20.9M
2
SCM
Suvretta Capital Management
New York
+$19.2M
3
BlackRock
BlackRock
New York
+$17.8M
4
CS
Candriam SCA
Luxembourg
+$11.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.21M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$33M
2
FCM
Farallon Capital Management
California
-$15.9M
3
B
Braidwell
Connecticut
-$12.9M
4
SC
Stempoint Capital
New York
-$11.2M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$8.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIG
201
American International Group
New York
– -$386K -38,976 Closed
DM
202
Deerfield Management
New York
– -$334K -33,714 Closed
Simplex Trading
203
Simplex Trading
Illinois
– -$233K -25,795 Closed
Vontobel Holding
204
Vontobel Holding
Switzerland
– -$208K -21,000 Closed
CSS
205
Cubist Systematic Strategies
Connecticut
– -$205K -20,705 Closed
Koshinski Asset Management
206
Koshinski Asset Management
Illinois
– -$198K -20,000 Closed
QL
207
Quarry LP
New York
– -$168K -17,000 Closed
QT
208
Quantbot Technologies
New York
– -$121K -12,200 Closed
NRD
209
Nebula Research & Development
New York
– -$110K -11,100 Closed
RJFSA
210
Raymond James Financial Services Advisors
Florida
– -$106K -10,675 Closed
CFM
211
Catalyst Funds Management
Australia
– -$85.2K -8,600 Closed
A
212
AlphaQuest
New York
– -$63.9K -6,452 Closed
MLICM
213
Metropolitan Life Insurance Company (MetLife)
New York
– -$43.9K -4,431 Closed
AWM
214
Avior Wealth Management
Nebraska
– -$218 -22 Closed
5 6 7 8
9

ARQT Hedge Fund Activity: Q2 2024 in Review

186 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2024, worth a combined $1.18B — down 5% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ARQT positions and 29 closed out — a net gain of 18 holders — while 59 added to existing stakes and 55 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $20.9M. The largest seller was State Street, cutting an estimated $33M.

  • 186 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2024, up from 168 in Q1 2024.
  • Funds reported $1.18B of Arcutis Biotherapeutics stock for Q2 2024, down 5% quarter-over-quarter.
  • 47 funds opened new Arcutis Biotherapeutics positions in Q2 2024 and 29 closed out, a net change of +18 holders.
  • The largest Arcutis Biotherapeutics buyer in Q2 2024 was Rubric Capital Management (New York), an estimated $20.9M added.
  • The largest Arcutis Biotherapeutics seller in Q2 2024 was State Street, an estimated $33M sold.

Based on aggregated 13F filings for Q2 2024.